# CJC-1295

> Source: https://peptidestogo.com/peptides/cjc-1295/
> Last updated October 25, 2026 · PeptidesToGo Editorial Team · Educational, not medical advice

GHRH analog

**Status:** Not FDA-approved · compounded · Prescription only

**How it is delivered:** Injection — weekly for the DAC form, nightly for the no-DAC form.

CJC-1295 is a synthetic, structurally modified version of growth hormone-releasing hormone — the signal your hypothalamus sends to tell your pituitary to release GH. It’s based on the first 29 amino acids of native GHRH, with four substitutions that block the enzymes that normally chew GHRH up in minutes. The result is a molecule that lasts days instead of minutes.

The version most clinicians prescribe carries an additional modification called a Drug Affinity Complex, or DAC. Once injected, the DAC binds covalently to a protein in your blood called serum albumin, anchoring the peptide in circulation. A single injection raises growth hormone and IGF-1 for roughly a week. The no-DAC version — sometimes called Modified GRF 1-29 — produces a sharp pulse of GH and then clears in about 30 minutes. These are pharmacologically distinct molecules that share a backbone, and the choice between them depends on whether you want sustained elevation or preserved pulsatility.

> “CJC-1295 is what happens when you take the body’s own GH-release signal and engineer it to last a workweek instead of a few minutes.”

The deep mechanistic detail — receptor binding, JAK2-STAT5 signaling, downstream IGF-1 production through PI3K/Akt/mTOR — lives on our PeptideWellness deep-dive. What matters here is that CJC-1295 works by prompting your pituitary to release more of its own GH, rather than supplying GH from outside.

Last updated October 25, 2026 · PeptidesToGo Editorial Team ·
[Educational, not medical advice](https://peptidestogo.com/legal/medical-disclaimer/)

## Who it's for (or who should avoid)

### What it's aimed at

CJC-1295 protocols are most commonly prescribed for:

- **Body composition goals** — lean-mass gain and fat-distribution shifts, particularly in combination with structured training
- **Recovery** — athletes managing chronic overuse injuries or looking to shorten recovery windows between sessions
- **Sleep quality** — patients reporting poor slow-wave sleep or fragmented sleep architecture
- **Age-related GH decline** — older adults whose endogenous GH secretion has dropped and who are looking to restore a more youthful axis
- **Performance optimization** — stacked with ipamorelin or other GHRPs for synergistic GH release

### Who should avoid it

- Anyone with an active or recent cancer — IGF-1 is a growth signal, and sustained elevation has been associated epidemiologically with increased risk of prostate and colorectal cancer
- People with pre-existing insulin resistance or diabetes — GH is a counter-regulatory hormone to insulin, and sustained elevation can worsen glucose handling
- Anyone pregnant, breastfeeding, or planning a pregnancy in the near term — no controlled human data
- Competitive athletes subject to WADA testing — CJC-1295 is a prohibited substance
- Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 — theoretical concern with sustained GH-axis stimulation

Nobody has run the trial that would tell you when to expect anything. The human evidence for CJC-1295 paired with ipamorelin is, as the hub puts it, essentially absent — what a growth-hormone secretagogue does in healthy adults, at what dose and for how long, is unknown. Treat the stages below as how clinicians describe using it, not as a schedule. They also assume consistent training and recovery habits.

## Route, dose and course

**Used for:** Sustained GH elevation for recovery, body composition and sleep

**How it’s taken:** Subcutaneous injection. The DAC form is dosed weekly; the no-DAC form nightly or several times a week.

**Doses sellers list and trials:** Rx Peps Direct sells it only blended with ipamorelin: 0.4 mg CJC-1295 (no-DAC) plus 0.4 mg ipamorelin per injection, no frequency given. The DAC form was tested in a 2006 trial at single doses of 30 and 60 µg/kg, the best tolerated. — No dose is approved for CJC-1295. We searched the sellers' own pages so you don't have to; the figures are theirs, not a recommendation. Your prescriber sets the dose. Where these figures come from: Rx Peps Direct peptide list (checked Oct 16, 2026) · Teichman et al. 2006, J Clin Endocrinol Metab (checked Oct 16, 2026)

**Cycle:** Not published — None of the sellers we checked publishes a cycle.

**Legal status:** Not FDA-approved, so there is no label to prescribe off. Prepared by a compounding pharmacy on prescription, though it is on no 503A list authorising that.

**What it costs:** About $150 a month — From the sellers' own pages on November 4, 2026; some sell it per vial or unit instead. Each figure, with what it leaves out, is in the table under “Can I actually get it?”. Sold combined with ipamorelin; no seller we track prices CJC-1295 on its own.

CJC-1295 is prescribed as a subcutaneous injection. The DAC form is typically dosed weekly; the no-DAC form is dosed nightly or several times per week.

What sellers and trials publish (we checked on 16 October 2026):

- **DAC form:** the 2006 trial gave single and repeated subcutaneous doses; 30 and 60 µg/kg were the best tolerated ([Teichman et al.](https://pubmed.ncbi.nlm.nih.gov/16352683/))
- **No-DAC form (Mod GRF 1-29):** [Rx Peps Direct](https://www.rxpepsdirect.com/peptides) sells it only blended with ipamorelin, 0.4 mg of each per injection, and does not say how often. No dose is approved
- **Cycling:** none of the sellers we checked publishes one
- **Stacking:** [Rx Peps Direct](https://www.rxpepsdirect.com/peptides) sells CJC-1295 only blended with ipamorelin; the two act on different pituitary receptors, but no human trial has tested the pair. Our [CJC-1295 + ipamorelin stack guide](https://peptidestogo.com/stacks/cjc-1295-ipamorelin/) covers why clinics pair them

Reconstitution typicall

## No measured timeline

No human trial has measured how soon CJC-1295 works or how long any effect lasts, and we found no source we trust for a week-by-week picture, so we do not draw one. Agree with your prescriber what you will measure and when you will check it.

## Available · from about $150/mo

Every headline price in this market excludes something. These are normalized to a
 calendar month, cheapest first, with the exclusion spelled out — the published figure
 is the footnote under it.

| Provider | From, per month | What that figure excludes | Coverage | Their own site |
| --- | --- | --- | --- | --- |
| [Live Vital](https://peptidestogo.com/providers/live-vital/) — Physician-led, monthly pricing, Draper UT | $150 (read 2026-11-04) | The dose the figure buys, which is not published; sold as a 2-month subscription, $299 every 2 months. | All 50, stated | [Go to site ↗](https://livevital.io/) |
| [Defy Medical](https://peptidestogo.com/providers/defy-medical/) — Tampa clinic, physician-led | No price for this compound | Peptides are priced per vial rather than per month, and neither the consultation nor the lab work that has to precede it is priced anywhere on the site. | Not published | [Go to site ↗](https://www.defymedical.com/) |
| PeRx — Peptide-only telehealth, Wellness MD Group PC | No price for this compound | The only peptide figure on the site is a floor for the whole menu — treatment plans "starting at $199" — so there is no price for any individual compound. The provider review is included; there is no separate consultation fee. | All 50, stated | [Go to site ↗](https://www.perxpeptides.com/) |
| [RxPepsDirect](https://peptidestogo.com/providers/rxpepsdirect/) — Per-vial prices, 503A pharmacy in Texas | $100 per vial (read 2026-11-04) | The $39 telehealth visit, charged per order. | A named list | [Go to site ↗](https://rxpepsdirect.com/) |

### Will it work where you live?

Most sellers claim all fifty states or publish nothing about coverage; a few name
 the states they serve or the ones they exclude, and the Coverage column says which.
 Either way it is the seller's own claim, so we can't filter this list by state
 without inventing a fact. What we can tell you is which state-level rules decide
 access: telehealth rules, non-resident pharmacy licensing, and who is allowed to
 prescribe.

[What shapes access in your state →](https://peptidestogo.com/tools/state-checker/)

### Prices and providers change. We keep track.

## Questions we get about CJC-1295

### Is CJC-1295 FDA-approved?

No — it's not an FDA-approved drug and isn't sold at retail pharmacies. There is no approved label for it to be prescribed off; licensed clinicians prescribe it and compounding pharmacies prepare it. It also has no lawful compounding route: the FDA removed CJC-1295 from its Category 2 "significant safety risk" list after the nominations were withdrawn in 2024, but as of May 2026 it's on no 503A category list and hasn't been added to the 503A bulks list that authorizes standard compounding — so no compounding pathway applies to it. Confirm current availability with your provider.

### Is it legal?

Not to compound, even with a prescription. Section 503A lets a pharmacy compound only from an ingredient of an FDA-approved drug, a substance with a USP monograph or one on the FDA's 503A bulks list, and the FDA's interim policy adds its category 1 while it decides. CJC-1295 is in none of these: the FDA took it off its category 2 safety list in September 2024, when the nomination was withdrawn, and has not added it to the list. Some telehealth providers prescribe it anyway and have a 503A pharmacy prepare it, and availability varies by formulation (DAC vs. no-DAC). Buying it from "research chemical" sellers without a prescription is not a lawful supply route for human use, and the quality of those products is untested. WADA prohibits CJC-1295 for competitive athletes. Availability can vary by state — confirm current access with the provider or your clinician.

### Are there side effects?

In the published Phase 1 trial, reported side effects were mild: injection-site reactions, occasional local hives, and no serious adverse events over 49 days. Post-market reports in FDA's database include chronic kidney disease and reports flagged as "drug ineffective," though these are uncontrolled and don't establish causation. Theoretical concerns include insulin resistance (GH is a counter-regulatory hormone), fluid retention, and IGF-1's association with certain cancers in epidemiological studies. Discuss your full medical history with your provider.

### Can I take it with my current medications?

No interaction data worth the name exists — the human evidence for CJC-1295 is thin enough that nobody has characterized how it behaves alongside other drugs. Always disclose your full medication list — including supplements and any other peptides — to your provider before starting.

### How much does it cost?

In the price table on this page, the monthly figure is about $150, read on November 4, 2026. Some sellers price it per vial or unit instead, shown in the same table. Nobody we track prices CJC-1295 alone: those figures are for CJC-1295 combined with ipamorelin. Its regulatory position explains the scarcity: the FDA put it on the Category 2 list in 2023 and pulled it off again in 2024 to route it through the advisory process, and it was not among the seven peptides reviewed in July 2026. Expect the DAC and no-DAC versions to price differently. Insurance does not cover compounded medications.

We publish no medical reviewer by design. Every claim on this page traces to a
 source we hold on file, and the reviewed write-up with those citations lives on our
 hub.
[Read the full research on PeptideWellness ↗](https://peptidewellnessusa.com/peptides/cjc-1295/)

## Commonly stacked with

## Related peptides